You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Lexicon Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for LEXICON PHARMS INC, and what generic alternatives to LEXICON PHARMS INC drugs are available?

LEXICON PHARMS INC has one approved drug.

There are three US patents protecting LEXICON PHARMS INC drugs.

There are seventy-one patent family members on LEXICON PHARMS INC drugs in thirty-three countries and twelve supplementary protection certificates in eleven countries.

Summary for Lexicon Pharms Inc
International Patents:71
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Lexicon Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 7,781,577 ⤷  Sign Up Y Y ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 8,217,156 ⤷  Sign Up Y Y ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 8,476,413 ⤷  Sign Up Y Y ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-002 May 26, 2023 RX Yes Yes 7,781,577 ⤷  Sign Up Y Y ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 8,476,413 ⤷  Sign Up Y Y ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up
Lexicon Pharms Inc INPEFA sotagliflozin TABLET;ORAL 216203-001 May 26, 2023 RX Yes No 8,217,156 ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Lexicon Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2089361 CA 2019 00042 Denmark ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430
2089361 2019/044 Ireland ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361 1990043-0 Sweden ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430
2089361 42/2019 Austria ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 (MITTEILUNG) 20190430
2089361 132019000000113 Italy ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYNQUISTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1363, 20190430
2089361 301003 Netherlands ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZIN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1363 20190430
2089361 C201930054 Spain ⤷  Sign Up PRODUCT NAME: SOTAGLIFLOZINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1363; DATE OF AUTHORISATION: 20190426; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1363; DATE OF FIRST AUTHORISATION IN EEA: 20190426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.